# Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

> **NCT01582152** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Brain Neoplasms
- Central Nervous System Neoplasms

## Interventions

- **DRUG:** TPI287
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01582152
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Phase 2 part of the trial will no longer continue since the protocol competes with another TPI287 protocol in outside institution supported by the sponsor.
- **Last updated:** 2019-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01582152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01582152, "Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01582152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*